Get the Stockscreener App
0.5051
18.99%
0.0806
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Vaxart Inc stock is traded at $0.5051, with a volume of 5.75M.
It is up +18.99% in the last 24 hours and up +44.77% over the past month.
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
See More
Previous Close:
$0.4245
Open:
$0.43
24h Volume:
5.75M
Relative Volume:
2.96
Market Cap:
$115.27M
Revenue:
$9.10M
Net Income/Loss:
$-82.47M
P/E Ratio:
-0.8709
EPS:
-0.58
Net Cash Flow:
$-72.32M
1W Performance:
+20.38%
1M Performance:
+44.77%
6M Performance:
-12.93%
1Y Performance:
-50.48%
1-Day Range:
$0.4278
$0.54
1-Week Range:
$0.37
$0.54
52-Week Range:
$0.285
$1.07
Vaxart Inc Stock (VXRT) Company Profile
Name
Vaxart Inc
Sector
Industry
Phone
(650) 550-3500
Address
170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VXRT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VXRT
Vaxart Inc
|
0.5051 | 95.76M | 9.10M | -82.47M | -72.32M | -0.58 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Vaxart Inc Stock (VXRT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-24 | Initiated | Oppenheimer | Outperform |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Nov-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-29-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jun-24-21 | Initiated | Jefferies | Buy |
| Jun-11-21 | Initiated | Piper Sandler | Overweight |
| Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
View All
Vaxart Inc Stock (VXRT) Latest News
Vaxart Approves Resolutions to Narrow Proposed Reverse - GlobeNewswire
Vaxart seeks approval for reverse stock split to retain Nasdaq listing By Investing.com - Investing.com South Africa
Vaxart Limits Reverse Stock Split To 1-for-20 In Response To Shareholder Feedback - Nasdaq
Vaxart Board Approves Reverse Split Proposal - TipRanks
Vaxart seeks approval for reverse stock split to retain Nasdaq listing - Investing.com Nigeria
Vaxart signals cash runway into Q1 2026 while advancing COVID-19 and norovirus vaccine programs - MSN
Vaxart (VXRT) Eyes Reverse Stock Split to Secure Nasdaq Listing | VXRT Stock News - GuruFocus
Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting | VXRT Stock News - GuruFocus
Vaxart Makes Last-Minute Changes to Reverse Split PlanCritical Nasdaq Deadline Approaches - Stock Titan
Vaxart gets nod to expand COVID-19 pill vaccine trial By Investing.com - Investing.com South Africa
Vaxart, Inc. Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2B Covid-19 Trial - marketscreener.com
Vaxart (VXRT) Secures BARDA Approval for Next Phase of COVID-19 Vaccine Trial | VXRT Stock News - GuruFocus
Vaxart Receives BARDA Approval for Phase 2b Trial - TipRanks
Vaxart gets nod to expand COVID-19 pill vaccine trial - Investing.com Australia
Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial - GlobeNewswire
Revolutionary Oral COVID Pill Vaccine Gets $460M BARDA Backing for Massive 10,000-Patient Trial - Stock Titan
Vaxart (VXRT) Rises After Positive Trial Results for Norovirus V - GuruFocus
Vaxart Publishes Positive, Complete Data from a Phase 2b - GlobeNewswire
Vaxart stock climbs on positive study of pill-based norovirus vaccine - MSN
Vaxart (VXRT) Appoints New CFO Amid Leadership Change | VXRT Sto - GuruFocus
Vaxart (VXRT) Unveils Promising Results from Phase 2b Norovirus Vaccine Study | VXRT Stock News - GuruFocus
Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine - The Manila Times
Revolutionary Oral Pill Vaccine Reduces Norovirus Infection by 30% in Landmark Phase 2b Trial - Stock Titan
Vaxart, Inc. (NASDAQ:VXRT) Q1 2025 Earnings Call Transcript - Insider Monkey
Vaxart Inc (VXRT) Q1 2025 Earnings Call Highlights: Strategic Progress Amidst Challenges - Yahoo Finance
Vaxart Inc Q1 2025 Earnings: EPS of -$0.10 and Revenue of $9.55 Million Meet Estimates - GuruFocus
Vaxart Reports Q1 2025 Progress and Financials - TipRanks
Vaxart (VXRT) Advances COVID-19 and Norovirus Vaccine Trials - GuruFocus
Vaxart Q1 2025 Earnings Call Transcript - MarketBeat
Vaxart Q1 Net Loss Narrows, Revenue Rises; Jeroen Grasman Named CFO - marketscreener.com
Vaxart Appoints Jeroen Grasman as New CFO - TipRanks
Vaxart Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Vaxart appoints Jeroen Grasman as new CFO - Investing.com Australia
Vaxart appoints Jeroen Grasman as new CFO By Investing.com - Investing.com Nigeria
Vaxart, Inc. SEC 10-Q Report - TradingView
Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results - The Manila Times
Vaxart Unlocks $460M COVID Vaccine Trial Funding, Reports Strong Pipeline Progress in Q1 2025 - Stock Titan
Vaxart Appoints Jeroen Grasman as Chief Financial Officer - GlobeNewswire
Former Genentech Executive Takes CFO Role at Vaxart to Accelerate Oral Vaccine Development - Stock Titan
Vaxart (VXRT) Proposes Reverse Stock Split to Maintain Nasdaq Li - GuruFocus
Vaxart Proposes Reverse Stock Split to Avoid Delisting - TipRanks
Vaxart, Inc. Encourages Stockholders to Approve Reverse Stock Split Proposal to Maintain Nasdaq Listing - Nasdaq
Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement - GlobeNewswire
'It's a mess out there': More biotech layoffs mean stiff competition for jobs at emerging companies - The Business Journals
Vaxart Resumes COVID-19 Vaccine Trial After Government Lift - TipRanks
Vaxart (VXRT) Advances Vaccine Efforts Amid Market Challenges | - GuruFocus
Vaxart seeks stockholder approval for reverse split - Investing.com
Vaxart seeks stockholder approval for reverse split By Investing.com - Investing.com Australia
Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress - The Manila Times
Vaxart CEO Letter: Government Lifts Trial Hold, Norovirus Study Fully Enrolled, Cash Extended to 2026 - Stock Titan
Vaxart to Host First Quarter 2025 Business Update and Financial - GuruFocus
Vaxart Inc Stock (VXRT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):